RFP, CGN and CGA Opportunities

The Alliance is a community dedicated to connecting healthcare education professionals to promote best practices that improve patient care. To help achieve this, we collect information on research proposals and grants offered through other healthcare-related organizations. If your company is interested in posting a request for grant applications, please contact the Alliance Business Office at

American Academy of Dermatology

The Academy bestows a number of prestigious awards to recognize the contributions of individuals to the specialty as well as offering various grants and scholarships to assist recipients in furthering their areas of study and broadening knowledge in the field of dermatology.

Program for Innovative Continuing Medical Education in Dermatology (PICMED)

The program was established to facilitate dermatologists' continuing education through support and development of innovative continuing medical education programs.

Available grants

  • Multi-year grant: Applicants may request up to $50,000 (direct costs only) for a two (2) year funding period.  2nd year funding will be contingent on 1st year milestones being met. 
  • Single-year grant: Applicants may request up to $10,000 (direct costs only) for a one (1) year project period. 

For more information regarding PICMED, please visit the AAD website.

Astellas, US Independent Medical Education and Pfizer Global Medical Grants

Astellas and Pfizer (collectively, the Companies) are committed to supporting high quality, evidence‐based independent medical education (IME) that seeks to improve the overall safety and quality of patient care and treatment. 

The purpose of this CGA is to encourage organizations to submit grant applications for independent CME/CE certified education designed to enhance understanding of increasingly complex treatment options and close knowledge gaps in prostate cancer. Knowledge gaps in prostate cancer which have been identified in the public healthcare landscape include:

  • Optimal management of cardiovascular risk factors in patients treated for prostate cancer.
  • Current and future treatment options in metastatic hormone-sensitive prostate cancer.

To access the application, click here.


Bioverativ, a Sanofi company is committed to supporting innovative, high quality, independent medical education for healthcare professionals (HCPs) that narrows unmet educational needs, maintains clinical excellence, and is designed to change HCP competence and performance, ultimately leading to improved outcomes in the patient communities that Bioverativ serves.

The intent of the Request for Educational Grant Applications (REGA) announcement is to notify experienced and eligible medical education providers that Bioverativ, a Sanofi company is interested in receiving applications for independent medical education activities pertinent to hemophilia or other rare blood disorders and are related to these therapeutic areas:

  • Hemophilia
  • Cold Agglutinin Disease

To access these Request for Grant Applications, please visit the Bioverativ Grants and Giving website.

Bristol-Myers Squibb

Bristol-Myers Squibb accepts funding requests within the following therapeutic areas of interest. As areas of interest and funding consideration may change periodically, please consult this website frequently. Please note that international funding opportunities may differ.

  • Cardiovascular
  • Immunoscience
  • Oncology
  • Virology
  • Genetically Defined / Rare Diseases

View Request for Proposals / for Education

EMD Serono, Inc. and Pfizer Inc.

EMD Serono, Inc. and Pfizer Inc. are collaborating to provide grant support for continuing professional education in the area of Immuno-Oncology. Immuno-Oncology is a top priority for EMD Serono and Pfizer. The global strategic alliance between our companies enables us to benefit from each other’s strengths and capabilities.

Date RFP Issued: November 1, 2018
Geographic Scope: United States only
Clinical Area: Immuno-Oncology in Renal Cell Carcinoma
Link to full RFP: Immuno-Oncology in Renal Cell Carcinoma
Due Date: November 19, 2018

Specific Area of Interest: Specifically for advanced RCC:

  1. Increase understanding of the rationale for consideration of IO combination therapies in the treatment of RCC including IO/VEGFR TKI.
  2. Increase awareness of when immunotherapy should be considered as a treatment option for patients with RCC to include patient selection, optimal drug combinations, and sequencing.
  3. Improve the early detection and management of IO and IO combination (IO/VEGFR TKI or IO/IO) related adverse events in RCC patients.

All applications must be submitted online through the EMD Serono Grant Management System, accessible at

Questions regarding this RFP should be directed to

ER/LA Opioid Analgesics REMS Program Companies (RPC)

The Opioid REMS Program Companies (RPC) Continuing Education (CE) Subteam would like to notify you that the 2018 Request for Application (RFA) for REMS-compliant accredited educational grant has been posted here. The 2018 CE Grant Cycle is open to all CE Providers interested in receiving funding for REMS-compliant accredited CE programs under RFA 090618. REMS-compliant educational activities must cover all portions of the revised FDA “Blueprint”, which can be accessed here.

The RPC intends to complete the review process and notify applicants of grant decisions as early as possible in the fourth quarter (October, November, December), 2018.

The deadline for submission of applications for this RFA is 11:59 pm ET, Monday, 9/10/2018. Beginning 6/29/2018, applications must be submitted through the RPC grant management system portal, accessible via this link:


Indivior supports independent medical education activities that provide for an increased understanding of scientific, clinical, or healthcare issues related to the company’s therapeutic areas of interest. 

Therapeutic areas of interest:

  • Opioid Use Disorder
  • Schizophrenia

To view open RFPs and complete details regarding grant submission, please visit the following site on a regular basis:

Insmed Incorporated

Insmed has funding to support independent accredited education intended to improve clinician knowledge, competence, and performance in the diagnosis and treatment of patients with Nontuberculous Mycobacterial (NTM) Lung Disease. Please refer to for grant submission requirements. For additional questions about the CGA process please contact Insmed Medical Education at Grant submissions should align to the specifications in the downloadable CGA.

Therapeutic Areas: Pulmonology/Infectious Disease
Nontuberculous Mycobacterial (NTM) Lung Disease
Focus Area: Local and Regional Education Activities

Submission Deadline: Rolling submissions accepted for 2018/2019
Download Call for Grants

Therapeutic Areas: Pulmonology/Infectious Disease
Nontuberculous Mycobacterial (NTM) Lung Disease
Focus Area: Education Activities associated with 2019 ATS and other Medical Society Conferences

Submission Deadline: at least 60 days prior to the requestors need for funding commitment, or based on society deadlines.
Download Call for Grants

Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)

The Centers for Medicare & Medicaid Services (CMS) recognizes the benefits of measure development by external stakeholders with specific knowledge of clinician and patient perspectives and needs, such as clinical specialty societies, clinical professional organizations, patient advocacy organizations, educational institutions, independent research organizations, health systems, and other entities. 

On March 2, 2018 CMS published the “Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program” on The purpose of this Funding Opportunity is to provide technical and funding assistance in the form of cooperative agreements to entities to develop, improve, update, or expand quality measures for use in the Quality Payment Program (QPP). 

For more information and to see the ‘Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program’ search by the title or the Catalog of Federal Domestic Assistance (CFDA) number, 93.986 on

Regeneron and Sanofi Genzyme Alliance

The Regeneron and Sanofi Genzyme Alliance seeks to close important medical educational gaps with regard to advanced cutaneous squamous cell carcinoma (CSCC) through consideration of grant proposals for 2019-2020 independent medical education activities. Target audiences include dermatologists, oncologists, Mohs surgeons, head and neck surgeons, and advanced-level practitioners via live and enduring distribution channels; please refer to the Request for Proposal for further details.

To view open RFPs and complete details, please visit this webpage

Pfizer Independent Grants for Learning & Change (IGLC)

The mission of Pfizer Independent Grants for Learning & Change is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. The Joint Commission is an independent, not-for-profit organization that accredits and certifies nearly 21,000 health care organizations and programs in the United States. 

To view open RFPs and complete details, please visit this webpage

Sanofi US

You are invited to submit a grant proposal to address the educational need outlined in the attached document. Please review and return your completed proposal via the Sanofi U.S. Grant Website at by 5p.m. EST on Wednesday, February 27, 2019. If a submission is not completed by this date, your proposal will not be accepted.

When entering proposal into the website, please reference the following:

Therapeutic Area: Oncology

Area of Interest: Multiple Myeloma

RFP Name: US MM RFP – 2/19

“Please note that an applicant may be ineligible to receive a grant in response to this RFP if the applicant has performed any services under contract with Sanofi U.S. during the last 12 months in connection with:

  • A consultant meeting; or
  • An advisory board meeting

in the same therapeutic area as this request for proposal (“RFP”). If the applicant has performed such services, please forward a copy of the contract immediately, prior to responding to the RFP, so that we can determine your eligibility. If not, please acknowledge this in your application writing.”

Please note that you must select the type of activity that you are proposing, i.e., Live, Enduring or Live and Enduring and answer the question, “Are you responding to an RFP” and Please select “US MM RFP – 2/19 “ from the RFP dropdown panel within the grant portal upon submitting your application for this RFP.

Submission instructions are available on the website. If you have a content question, please contact Malika Wicks at

Sanofi US Medical Affairs

You are invited to submit a grant proposal to address the educational need outlined in the attached document. Please submit your proposal via the Sanofi US Educational Grant website at by 5 p.m. EST on February 14, 2019. If a submission is not completed by this date, your proposal will not be accepted.

When entering proposal into the website, please reference the following:

RFP ID: Diabetes RFP 2019 Differences in Long-Acting Insulins
Therapeutic Area: Diabetes
Area of Interest: Long-acting insulins with a physiologic approach to glucose control

If you have any questions, please call the Diabetes Hotline at 866-841-4549 or email at

Seattle Genetics and Astellas Alliance

The Seattle Genetics and Astellas Alliance invites you to submit grant applications to identify and address the educational needs in the therapeutic area of Urothelial Carcinoma (UC). The purpose of this CGA is to encourage organizations to submit grant applications for in-depth independent educational needs assessment(s) designed to assess and understand the rapidly evolving educational needs of HCPs responsible for treatment decisions for patients with UC, including:

• Understanding of current and future treatment options in advanced and metastatic urothelial carcinoma
• Awareness and understanding of emerging therapeutic options for patients ineligible for chemotherapy or who have been previously treated with checkpoint inhibitors
• Awareness and understanding of differences in mechanism of action, efficacy, and safety profiles of novel agents in locally advanced and metastatic UC

To view the CGA, please click here

Shionogi Inc.

Shionogi accepts funding requests within the following therapeutic areas of interest.

  • Gram negative multidrug resistant infectious disease (ID)
  • Thrombocytopenia associated with chronic liver disease (CLD)
  • Opioid-induced Constipation (OIC)

The call for grants (CFG) opportunities will change on a quarterly basis.  Please consult our website to identify current opportunities.

Society for Academic Continuing Medical Education (SACME)

The Research Committee of the Society for Academic Continuing Medical Education (SACME) requests Letters of Intent (LOI) for original, scientific research related to physician and/or health professionals lifelong learning. Opportunities for research funding are one of the benefits of SACME membership. 

Proposals will not be restricted to a particular methodological approach or topic area within CME/CPD/IPE. However, the project must be theory based and methodologically sound. The finished work must be appropriate for publication in a health professions education journal (e.g. Journal of Continuing Education in the Health Professions, Academic Medicine) or equivalent peer reviewed journal, as well as for presentation at a future SACME Annual Meeting (Phil R. Manning Research Award Plenary) or CPD World Congress.

Funding: A grant will be awarded up to a total amount of $50,000 over two years. The next grant award decision will be made by the end of January 2019. The protocol for disbursement of funds is provided in a separate document. 

The submission process closes Tuesday, September 4, 2018Click here for additional information + submission details.

Vertex Pharmaceuticals

Vertex currently has funding to support an accredited, live symposium at the North American Cystic Fibrosis Conference (NACFC) 2018 Annual Meeting being held October 18th – 20th accompanied by an accredited web-based, enduring activity utilizing content from the symposium.

 Please refer to for grant submission requirements. For additional questions about the RFP process, please contact Vertex Grants at

Vertex is committed to supporting accredited, independent medical education programs and/or materials for healthcare professionals that aim to improve their skills and knowledge with the goal of improving patient outcomes. Consideration will be given to independent medical education that is high-quality, balanced, scientifically rigorous, free from commercial influence or bias and compliant with the PhRMA Code, ACCME guidelines, and applicable laws. 

Therapeutic Area: Cystic Fibrosis
Areas of Interest: Vertex is interested in supporting an innovative learning program that enhances the understanding of topics such as, but not limited to:

  • Early manifestations of Cystic Fibrosis
  • Strategies to intervene in an effort to ensure the best possible patient outcomes

Submission Deadline: Midnight, August 3rd, 2018
Download RFP